NanoViricides (NNVC) 10-Q 14 Feb 20 2020 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Dec. 31, 2019	Feb. 14, 2020
Document And Entity Information
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Dec. 31, 2019
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Entity Registrant Name	NANOVIRICIDES, INC.
Entity Central Index Key	0001379006
Current Fiscal Year End Date	--06-30
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Trading Symbol	NNVC
Entity Common Stock, Shares Outstanding		7,423,000
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Small Business	true

Balance Sheets

Balance Sheets - USD ($)	Dec. 31, 2019	Jun. 30, 2019
CURRENT ASSETS:
Cash and cash equivalents	$ 707,648	$ 2,555,207
Prepaid expenses	257,832	270,214
Deferred issuance costs	383,175
Total current assets	1,348,655	2,825,421
PROPERTY AND EQUIPMENT
Property and equipment	14,096,316	14,092,177
Accumulated depreciation	(4,210,604)	(3,864,930)
Property and equipment, net	9,885,712	10,227,247
TRADEMARK AND PATENTS
Trademark and patents	458,954	458,954
Accumulated amortization	(96,431)	(92,296)
Trademark and patents, net	362,523	366,658
OTHER ASSETS
Security deposits	3,515	3,515
Service agreements	17,852	25,672
Other assets	21,367	29,187
Total assets	11,618,257	13,448,513
CURRENT LIABILITIES:
Mortgage note payable - related party	1,062,337
Accounts payable	672,357	309,893
Accounts payable - related party	737,370	823,783
Accrued expenses	52,632	68,871
Total current liabilities	3,895,853	2,848,153
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY:
Common stock, $0.001 par value; 7,500,000 shares authorized, 3,870,572 and 3,844,921 shares issued and outstanding at December 31, 2019 and June 30, 2019, respectively	3,871	3,845
Additional paid-in capital	103,323,412	102,712,845
Accumulated deficit	(95,605,245)	(92,116,586)
Total stockholders' equity	7,722,404	10,600,360
Total Liabilities and Stockholders' Equity	11,618,257	13,448,513
Derivative liability - Warrants
CURRENT LIABILITIES:
Derivative liability - warrants	1,371,157	1,645,606
Series A Convertible Preferred Stock [Member]
STOCKHOLDERS' EQUITY:
Series A Convertible Preferred stock, $0.001 par value, 425,000 shares designated, 366,488 and 255,714 shares issued and outstanding, at December 31, 2019 and June 30, 2019, respectively	$ 366	$ 256

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2019	Jun. 30, 2019
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	7,500,000	7,500,000
Common stock, shares issued	3,870,572	3,844,921
Common stock, shares, outstanding	3,870,572	3,844,921
Series A Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	425,000	425,000
Preferred stock, shares issued	366,488	255,714
Preferred stock, shares outstanding	366,488	255,714

Statements of Operations

Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
OPERATING EXPENSES
Research and development	$ 1,012,085	$ 1,657,838	$ 2,494,490	$ 3,024,779
General and administrative	622,347	711,360	1,127,819	1,383,517
Total operating expenses	1,634,432	2,369,198	3,622,309	4,408,296
LOSS FROM OPERATIONS	(1,634,432)	(2,369,198)	(3,622,309)	(4,408,296)
OTHER INCOME (EXPENSE):
Interest income	784	15,565	6,001	37,749
Interest expense	(4,131)	0	(4,131)	0
Loss on issuance of Series A preferred stock for accounts payable - related party	(142,669)	0	(142,669)	0
Change in fair value of derivative	(147,078)	122,541	274,449	298,092
Other (expense) income	(293,094)	138,206	133,650	335,841
LOSS BEFORE INCOME TAX PROVISION	(1,927,526)	(2,230,992)	(3,488,659)	(4,072,455)
INCOME TAX PROVISION	0	0	0	0
NET LOSS	$ (1,927,526)	$ (2,230,992)	$ (3,488,659)	$ (4,072,455)
NET LOSS PER COMMON SHARE
Net loss per common share- basic and diluted	$ (0.50)	$ (0.64)	$ (0.91)	$ (1.18)
Weighted average common shares outstanding
Weighted average common shares outstanding- basic and diluted	3,853,858	3,469,193	3,849,437	3,464,246

Statement of Changes in Stockho

Statement of Changes in Stockholders' Equity - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Jun. 30, 2018	$ 227	$ 3,459	$ 101,352,724	$ (83,692,146)	$ 17,664,264
Balance (in shares) at Jun. 30, 2018	226,570	3,458,587
Series A Preferred stock issued for employee stock compensation	$ 27		55,001		55,027
Series A Preferred stock issued for employee stock compensation (in shares)	26,636
Common stock issued for consulting and legal services rendered		$ 10	79,450		79,460
Common stock issued for consulting and legal services rendered (in shares)		9,576
Stock options issued for compensation			11,920		11,920
Warrants issued to Scientific Advisory Board	$ 0	$ 0	1,543	0	1,543
Common shares issued for Directors fees		$ 1	7,499		7,500
Common shares issued for Directors fees (in shares)		966
Net loss				(1,841,463)	(1,841,463)
Balance at Sep. 30, 2018	$ 254	$ 3,470	101,508,137	(85,533,609)	15,978,251
Balance (in shares) at Sep. 30, 2018	253,206	3,469,129
Balance at Jun. 30, 2018	$ 227	$ 3,459	101,352,724	(83,692,146)	17,664,264
Balance (in shares) at Jun. 30, 2018	226,570	3,458,587
Net loss					(4,072,455)
Balance at Dec. 31, 2018	$ 254	$ 3,476	101,601,431	(87,764,601)	13,840,559
Balance (in shares) at Dec. 31, 2018	253,592	3,457,070
Balance at Sep. 30, 2018	$ 254	$ 3,470	101,508,137	(85,533,609)	15,978,251
Balance (in shares) at Sep. 30, 2018	253,206	3,469,129
Series A Preferred stock issued for employee stock compensation			53,621		53,621
Series A Preferred stock issued for employee stock compensation (in shares)	386
Common stock issued for consulting and legal services rendered		$ 4	26,996		27,000
Common stock issued for consulting and legal services rendered (in shares)		4,198
Warrants issued to Scientific Advisory Board			1,429		1,429
Common shares issued for Directors fees		$ 2	11,248		11,250
Common shares issued for Directors fees (in shares)		1,743
Net loss				(2,230,992)	(2,230,992)
Balance at Dec. 31, 2018	$ 254	$ 3,476	101,601,431	(87,764,601)	13,840,559
Balance (in shares) at Dec. 31, 2018	253,592	3,457,070
Balance at Jun. 30, 2019	$ 256	$ 3,845	102,712,845	(92,116,586)	10,600,360
Balance (in shares) at Jun. 30, 2019	255,714	3,844,921
Series A Preferred stock issued for employee stock compensation	$ 0	$ 0	51,398	0	51,398
Series A Preferred stock issued for employee stock compensation (in shares)	387	0
Common stock issued for consulting and legal services rendered		$ 6	26,994		27,000
Common stock issued for consulting and legal services rendered (in shares)		6,201
Warrants issued to Scientific Advisory Board			908		908
Common shares issued for Directors fees		$ 3	11,247		11,250
Common shares issued for Directors fees (in shares)		2,553
Net loss				(1,561,133)	(1,561,133)
Balance at Sep. 30, 2019	$ 256	$ 3,854	102,803,392	(93,677,719)	9,129,783
Balance (in shares) at Sep. 30, 2019	256,101	3,853,675
Balance at Jun. 30, 2019	$ 256	$ 3,845	102,712,845	(92,116,586)	10,600,360
Balance (in shares) at Jun. 30, 2019	255,714	3,844,921
Net loss					(3,488,659)
Balance at Dec. 31, 2019	$ 366	$ 3,871	103,323,412	(95,605,245)	7,722,404
Balance (in shares) at Dec. 31, 2019	366,488	3,870,572
Balance at Sep. 30, 2019	$ 256	$ 3,854	102,803,392	(93,677,719)	9,129,783
Balance (in shares) at Sep. 30, 2019	256,101	3,853,675
Series A Preferred stock issued for employee stock compensation			49,394		49,394
Series A Preferred stock issued for employee stock compensation (in shares)	387
Series A Preferred Stock issued for accounts paayble-related party	$ 100		392,569		392,669
Series A Preferred Stock issued for accounts payable-related party (in Shares	100,000
Series A Preferred Stock issued for loan origination fee	$ 10		39,291		39,301
Series A Preferred Stock issued for interest (in shares)	10,000
Common stock issued for consulting and legal services rendered		$ 12	26,988		27,000
Common stock issued for consulting and legal services rendered (in shares)		11,932
Warrants issued to Scientific Advisory Board			533		533
Common shares issued for Directors fees		$ 5	11,245		11,250
Common shares issued for Directors fees (in shares)		4,965
Net loss				(1,927,526)	(1,927,526)
Balance at Dec. 31, 2019	$ 366	$ 3,871	$ 103,323,412	$ (95,605,245)	$ 7,722,404
Balance (in shares) at Dec. 31, 2019	366,488	3,870,572

Statements of Cash Flows

Statements of Cash Flows - USD ($)	6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (3,488,659)	$ (4,072,455)
Adjustments to reconcile net loss to net cash used in operating activities
Preferred shares issued as compensation	100,792	108,648
Loss on issuance of preferred shares for accounts payable- related party	142,669	0
Common shares issued as compensation and for services	76,500	125,210
Warrants granted to Scientific Advisory Board	1,441	2,972
Stock-based compensation expense	0	11,920
Depreciation	345,674	343,135
Amortization of loan origination fees	1,638	0
Amortization	4,135	4,136
Change in fair value of derivative liability	(274,449)	(298,092)
Changes in operating assets and liabilities:
Prepaid expenses	12,382	71,309
Other assets	7,820	2,850
Accounts payable	362,464	442
Accounts payable - related party	163,587	693,362
Accrued expenses	(16,239)	(114,000)
NET CASH USED IN OPERATING ACTIVITIES	(2,560,245)	(3,120,563)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(4,139)	(57,536)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from note payable to related party	1,100,000	0
Deferred issuance costs	(383,175)	0
NET CASH PROVIDED BY FINANCING ACTIVITIES	716,825	0
NET CHANGE IN CASH AND CASH EQUIVALENTS	(1,847,559)	(3,178,099)
Cash and cash equivalents at beginning of period	2,555,207	7,081,771
Cash and cash equivalents at end of period	707,648	3,903,672
SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:
Interest paid	0	0
Non-cash Financing and Investing Activities:
Series A preferred stock issued for accounts payable-related party	250,000	0
Series A preferred stock issued for loan origination fee	$ 39,301	$ 0

Organization ,Nature of Busines

Organization ,Nature of Business and Reverse Stock Split	6 Months Ended
	Dec. 31, 2019
Organization ,Nature of Business and Reverse Stock Split
Organization ,Nature of Business and Reverse Stock Split	Note 1 – Organization, Nature of Business and Reverse Stock Split NanoViricides, Inc. (the “Company”) is a nano-biopharmaceutical research and development company specializing in the discovery, development, and commercialization of drugs to combat viral infections using its unique and novel nanomedicines technology. NanoViricides is also unique in the bio-pharma field in that it possesses its own state of the art facilities for the design, synthesis, analysis and characterization of the nanomedicines that we develop, as well as for production scale-up, and c-GMP-like production in quantities needed for human clinical trials, where our design, development, and production work is performed. The biological studies such as the effectiveness, safety, bio-distribution and Pharmacokinetics/Pharmacodynamics on our drug candidates are performed by external collaborators and contract organizations. We are a company with several drugs in various stages of early development. In our lead antiviral program against herpes viruses, i.e. the HerpeCide™ program alone, we have drug candidates against at least five indications at different stages of development. Of these, the Company is advancing the shingles drug candidate towards human clinical trials. The IND-enabling Safety/Toxicology studies required for doing so began as of the end of December 2018 at the contract research organization (“CRO”) Bioanalytical Systems, Inc.(“BASi”), in Indiana. If successful, the Company intends to file an IND after receiving a formal report on these studies from BASi in the near future. In addition, our drug candidates against HSV‑1 “cold sores” and HSV‑2 “genital herpes” are in advanced studies and are expected to follow the shingles drug candidate into human clinical trials. Shingles in adults and chicken pox in children is caused by the same virus, namely VZV (Varicella-zoster virus, aka HHV‑3 or human herpesvirus‑3). There are estimated to be approximately 120,000‑150,000 annual chickenpox cases in the USA in the post-vaccination-era, i.e. since childhood vaccination with the live attenuated varicella virus Oka strain has become standard. In addition, we have drugs in development against all influenzas in our FluCide™ program, as well as drug candidates against HIV/AIDS, Dengue, Ebola/Marburg, and other viruses. Our drugs are based on several patents, patent applications, provisional patent applications, and other proprietary intellectual property held by TheraCour Pharma, Inc. (“TheraCour”), to which we have broad, exclusive licenses. The first license agreement we executed with TheraCour on September 1, 2005, gave us an exclusive, worldwide license for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Herpes Simplex Virus (HSV), Influenza and Asian Bird Flu Virus. On February 15, 2010, the Company executed an Additional License Agreement with TheraCour. Pursuant to the Additional License Agreement, the Company was granted exclusive licenses for technologies, developed by TheraCour, for the development of drug candidates for the treatment of Dengue viruses, Ebola/Marburg viruses, Japanese Encephalitis, viruses causing viral Conjunctivitis (a disease of the eye) and Ocular Herpes. We hold exclusive licenses for developing drugs against several different viruses from TheraCour, including HSV-1 and HSV-2. In addition, on November 1, 2019, NanoViricides entered into a world-wide, exclusive, sub-licensable, license to use, promote, offer for sale, import, export, sell and distribute drugs that treat VZV infections, using TheraCour’s proprietary as well as patented technology and intellectual property. The discovery of ligands and polymer materials as well as formulations, the chemistry and chemical characterization, as well as process development and related work will be performed by TheraCour under the same compensation terms as prior agreements between the parties, with no duplication of costs allowed. The Company was not required to make any upfront payments to TheraCour and agreed to the following milestone payments to TheraCour; the issuance of 75,000 shares of the Company's Series A Convertible Preferred Stock upon the grant of an IND Application; $1,500,000 in cash upon completion of Phase I Clinical Trials; $2,500,000 in cash upon completion of Phase II clinical trials; and $5,000,000 in cash upon completion of Phase III clinical trials. Reverse Stock Split On September 24, 2019 (the “Effective Date”), the Company effected a reverse stock split of its outstanding shares of common stock and shares of preferred stock at a ratio of one-for-twenty (the “Reverse Stock Split”). The Reverse Stock Split, which was approved by the Company’s Board of Directors under authority granted under the laws of the State of Nevada, was consummated pursuant to a Certificate of Amendment filed with the Secretary of State of Nevada on September 23, 2019 (the “Certificate of Amendment”). Unless the context otherwise requires, all references in these financial statements to shares of the Company’s common stock and series A preferred stock, including prices per share of its common stock and Series A preferred stock, reflect the Reverse Stock Split. Fractional shares were not issued, and the final number of shares were rounded up to the next whole share.

Liquidity

Liquidity	6 Months Ended
	Dec. 31, 2019
Liquidity
Liquidity	Note 2 - Liquidity The Company’s financial statements have been prepared assuming that it will continue as a going concern, which contemplates continuity of operations, realization of assets and liquidation of liabilities in the normal course of business. As reflected in the financial statements, the Company has an accumulated deficit at December 31, 2019 of approximately $95.6 million and a net loss of approximately $3.5 million and net cash used in operating activities of approximately $2.6 million for the six months then ended. In addition, the Company has not generated any revenues and no revenues are anticipated in the foreseeable future. Since May 2005, the Company has been engaged exclusively in research and development activities focused on developing targeted antiviral drugs. The Company has not yet commenced any product commercialization. Such losses are expected to continue for the foreseeable future and until such time, if ever, as the Company is able to attain sales levels sufficient to support its operations. There can be no assurance that the Company will achieve or maintain profitability in the future. As of December 31, 2019, the Company had available cash and cash equivalents of approximately $0.7 million. Management adjusted its planned expenditures, activities, and programs, in accordance with budgetary constraints and in accordance with its expectations of obtaining additional financing. The Company has made several adjustments to its past expenditures in the ensuing annual budget, eliminating several expenses including a reduction in workforce and consultants to the extent feasible without affecting its program of drug development. In addition, the Company has focused its efforts primarily on a single lead program to minimize cost outlays, namely, taking the shingles drug candidate against VZV into human clinical trials. Management’s budget indicates that these changes have freed up sufficient funds to allow for the ensuing costs of the external advanced IND-enabling studies of this drug candidate. Management has advanced several options for financing the net working capital deficit as well as to obtain additional funds that will be needed for future human clinical trials. On December 16, 2019, the Company entered into an Open End Mortgage Note with Anil Diwan, the Company's founder, Chairman and President, to loan the Company up to $2,000,000. As of December 31, 2019, the Company had drawn down $1.1 million on this note. On December 17, 2019, the Company entered into a Deferred Expense Exchange Agreement with TheraCour Pharma, Inc. (“TheraCour”), whereby TheraCour agreed to exchange a portion of the previously deferred development fees owed to TheraCour in the amount of $250,000 into 100,000 Series A preferred shares. On November 7, 2019, the Company engaged Aegis Capital Corp for an underwritten offering pursuant to a Form S-1 filing. On January 21, 2020, the Company entered into an underwriting agreement (the "Underwriting Agreement") with Aegis Capital Corp. Pursuant to the terms and conditions of the Underwriting Agreement, we agreed to issue and sell 2,500,000 shares of our common stock, par value $0.001 per share for $3.00 per share. We also granted the underwriter an option to purchase up to an additional 375,000 shares of our common stock (together with the Underwritten Shares, the "Shares") within 45 days after the date of the Underwriting Agreement to cover over-allotments, The offering was consummated on January 25, 2020. The Company sold the Underwritten Shares and the underwriter exercised its option to purchase an additional 375,000 shares of common stock at the public offering price of $3.00 per share. The net proceeds to the Company after underwriter's commission and agreed upon customary fees and expenses were approximately $7.8 million, before deducting the Company's legal and accounting expenses related to the Offering. See Note 11. In addition, the Company believes that it has several important milestones that it will be achieving in the ensuing year. Management believes that as it achieves these milestones, the Company would likely experience improvement in the liquidity of the Company’s stock, and would eventually improve the Company’s ability to raise funds on the public markets at terms that may be more favorable to the terms we are offered at present. The Company believes that its existing resources will be sufficient to fund its planned operations and expenditures for at least the next twelve months from the issuance of these financial statements. However, the Company will need to raise additional capital to fund its long term operations and research and development plans until it generates revenue which reaches a level sufficient to provide self-sustaining cash flows. There is no assurance that the Company will be successful in obtaining sufficient financing on terms acceptable to the Company. The Company believes that the management plan, the Company’s existing resources and access to the capital markets will permit the Company to fund planned operations and expenditures. However, the Company cannot provide assurance that its plans will not change or that changed circumstances will not result in the depletion of its capital resources more rapidly than it currently anticipates.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Dec. 31, 2019
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	Note 3 - Summary of Significant Accounting Policies Basis of Presentation – Interim Financial Information The accompanying unaudited interim financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10‑Q and Article 10 of Regulation S-X of the Securities and Exchange Commission for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. The accompanying financial statements and the information included under the heading “Management’s Discussion and Analysis or Plan of Operation” should be read in conjunction with our Company’s audited financial statements and related notes included in our Company’s Form 10‑K for the fiscal year ended June 30, 2019 filed with the SEC on August 23, 2019. For a summary of significant accounting policies, see the Company’s Annual Report on Form 10‑K for the fiscal year ended June 30, 2019 filed on August 23, 2019. Net Loss per Common Share Basic net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants and convertible preferred stock. The following table shows the number of potentially outstanding dilutive common shares excluded from the diluted net loss per common share calculation, as they were anti-dilutive: Potentially Outstanding Dilutive Common Shares For the For the Six Months Six Months Ended Ended December 31, 2019 December 31, 2018 Options and Warrants 375,012 221,174 Total potentially outstanding dilutive common shares 375,012 221,174 The Company has also issued 366,488 shares of Series A preferred stock to investors and others as of December 31, 2019. Only in the event of a “change of control” of the Company, each Series A preferred share is convertible to 3.5 shares of its new common stock. A “Change of Control” is defined as an event in which the Company’s shareholders become 60% or less owners of a new entity as a result of a change of ownership, merger or acquisition of the Company or the Company’s intellectual property. In the absence of a Change of Control event, the Series A preferred stock is not convertible into common stock, and does not carry any dividend rights or any other financial effects. At December 31, 2019, the number of potentially dilutive shares of the Company’s common stock into which these Series A preferred shares can be converted into is 1,282,708 and is not included in diluted earnings per share since the shares are contingently convertible only upon a change of control. Deferred Issuance Costs Deferred issuance costs consist of $383,175 of certain costs in connection with the Company’s S-1 registration and planned public offering. These costs together with any underwriter’s fees and discounts will be charged to additional paid-in capital upon closing of the public offering. note 11. Recently Issued Accounting Pronouncements In July 2017, the FASB issued Accounting Standards Update (“ASU”) No. 2017‑11. “Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features, II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Non-controlling Interests with a Scope Exception (“ASU 2017-11”) ASU 2017‑11 revises the guidance for instruments with down round features in Subtopic 815‑40, Derivatives and Hedging – Contracts in Entity’s Own Equity, which is considered in determining whether an equity-linked financial instrument qualifies for a scope exception from derivative accounting. An entity still is required to determine whether instruments would be classified in equity under the guidance in Subtopic 815‑40 in determining whether they qualify for that scope exception. If they do qualify, freestanding instruments with down round features are no longer classified as liabilities. ASU 2017‑11 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018, and early adoption is permitted, including adoption in an interim period. ASU 2017‑11 provides that upon adoption, an entity may apply this standard retrospectively to outstanding financial instruments with a down round feature by means of a cumulative-effect adjustment to the opening balance of accumulated deficit in the fiscal year and interim period adoption. The Company has adopted ASU 2017-11 retrospectively as of January 1, 2019. The adoption of this ASU did not have any impact on its financial statements. In June 2018, the FASB issued ASU 2018-07, “Compensation – Stock Compensation (Topic 718) (“ASU 2018-07”): Improvements to Nonemployee Share Based Payment Accounting,” which simplifies the accounting for non-employee share-based payment transactions. The amendments specify that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. Upon transition, non-employee awards are required to be measured at fair value as of the adoption date. The Company had adopted ASU 2018-07 as of July 1, 2019. The adoption of this ASU did not have a significant impact on its financial statements.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Dec. 31, 2019
Related Party Transactions
Related Party Transactions	Note 4 - Related Party Transactions Related Parties Related parties with whom the Company had transactions are: Related Parties Relationship Anil R. Diwan Chairman, President, acting CEO, significant stockholder and Director TheraCour Pharma, Inc. An entity owned and controlled by a significant stockholder As of December 31, June 30, 2019 2019 Account Payable – Related Party Pursuant to an Exclusive License Agreement we entered into with TheraCour, the Company was granted exclusive licenses in perpetuity for technologies developed by TheraCour for the virus types: HIV, HCV, Herpes, Asian (bird) flu, Influenza and rabies. In consideration for obtaining this exclusive license, we agreed: (1) that TheraCour can charge its costs (direct and indirect) plus no more than 30% of direct costs as a development fee and such development fees shall be due and payable in periodic installments as billed, (2) we will pay $2,000 or actual costs each month, whichever is higher for other general and administrative expenses incurred by TheraCour on our behalf, (3) to make royalty payments of 15% (calculated as a percentage of net sales of the licensed drugs) to TheraCour; (4) to pay an advance payment equal to twice the amount of the previous month’s invoice to be applied as a prepayment towards expenses. On October 2, 2018, the Company entered into an agreement with TheraCour for a waiver of the two months worth of prepaid balance advance of anticipated invoicing until the filing of an IND and the application of the current advance as a credit against current open invoices. Additionally, TheraCour agreed to defer $25,000 per month of development fees, beginning with July 2018 through December 31, 2019. On December 17, 2019, the Company entered into a Deferred Expense Exchange Agreement with TheraCour, whereby the Company and TheraCour agreed to the exchange of 100,000 shares of Series A preferred stock with a fair value of $392,669 for $250,000 previously deferred development fees owed to TheraCour, and recognized a loss on the exchange of $142,669. Accounts payable due TheraCour on the reporting date was $ 737,370 $ 823,783 For the three months ended For the six months ended December December December December 31, 31, 31, 31, 2019 2018 2019 2018 Property and Equipment During the reporting period, TheraCour acquired property and equipment on behalf of the Company from third party vendors and sold such property and equipment, at cost, to the Company $ — $ 7,408 $ 4,139 $ 7,408 For the three months ended For the six months ended December December December December 31, 31, 31, 31, 2019 2018 2019 2018 Research and Development Costs Paid to Related Party Development fees and other costs charged by TheraCour pursuant to exclusive License Agreements between TheraCour and the Company for the development of the Company’s drug pipeline. No royalties are due TheraCour from the Company at December 31, 2019 and June 30, 2019 $ 543,108 $ 899,184 $ 1,119,315 $ 1,745,872 Mortgage Note Payable - Related Party On December 16, 2019, the Company entered into an Open End Mortgage Note (the "Note") with Anil Diwan, the Company's founder, Chairman and President, to loan the Company up to $2,000,000 in two tranches of $1,000,000 (the "Loan"). The Note bears interest at the rate of 12% per annum and is secured by a mortgage granted against the Company’s headquarters. The unpaid principal balance is due and payable on December 15, 2020. The lender received 10,000 shares of the Company's Series A preferred stock as a loan origination fee which is to be amortized over the one year term of the loan using effective interest method. The fair value of the 10,000 shares of the Company’s Series A preferred stock when issued on December 16, 2019 was $39,301. The Series A preferred stock fair value is based on the greater of the i) the converted value to common at a ratio of 1:3.5; or ii) the value of the voting rights since the Holder would lose the voting rights upon conversion. for the assumptions used in calculating the fair value of the preferred shares. The conversion of the shares is triggered by a Change of Control. See note 7 for inputs used in calculation of fair value. Amortization expense on the loan origination fee was $1,638 for both the three and six months ended December 31, 2019. As of December 31, 2019, the Company has drawn down $1.1 million of this loan and may, at its option, draw down the remainder of the loan. Interest is payable only on the amount drawn down. The lender has escrowed $132,000 of interest payable pursuant to the Loan. For both the three and six months ended December 31, 2019, the Company incurred interest expense of $2,493 which reduced the interest escrow balance included in prepaid expenses. At December 31, 2019, mortgage note payable – related party consisted of: Mortgage note payable $ 1,100,000 Less: unamortized loan origination fee (37,663) $ 1,062,337

Property and Equipment

Property and Equipment	6 Months Ended
	Dec. 31, 2019
Property and Equipment
Property and Equipment	Note 5 - Property and Equipment Property and equipment, stated at cost, less accumulated depreciation consisted of the following: Property and equipment, stated at cost, less accumulated depreciation consisted of the following: December 31, June 30, 2019 2019 GMP Facility $ 8,020,471 $ 8,020,471 Land 260,000 260,000 Office Equipment 57,781 57,781 Furniture and Fixtures 5,607 5,607 Lab Equipment 5,752,457 5,748,318 Total Property and Equipment 14,096,316 14,092,177 Less Accumulated Depreciation (4,210,604) (3,864,930) Property and Equipment, Net $ 9,885,712 $ 10,227,247 Depreciation expense for the three months ended December 31, 2019 and 2018 were $172,863 and $171,815, respectively, and for the six months ended December 31, 2019 and 2018 were $345,674 and $343,135, respectively.

Trademark and Patents

Trademark and Patents	6 Months Ended
	Dec. 31, 2019
Trademarks and Patents
Trademarks and Patents	Note 6 - Trademark and Patents Trademark and patents, stated at cost, less accumulated amortization consisted of the following: December 31, June 30, 2019 2019 Trademarks and Patents $ 458,954 $ 458,954 Less Accumulated Amortization (96,431) (92,296) Trademarks and Patents, Net $ 362,523 $ 366,658 Amortization expense amounted to $2,067 and $2,067 for each of the three month periods ended December 31, 2019 and 2018 and $4,135 and $4,136 for the six months ended December 31, 2019 and 2018, respectively.

Equity Transactions

Equity Transactions	6 Months Ended
	Dec. 31, 2019
Equity Transactions
Equity Transactions	Note 7 - Equity Transactions On July 11, 2018 the Board of Directors approved an extension of the employment agreement with Dr. Anil Diwan, the Company’s President. Pursuant to the terms of the employment agreement, the Company’s Board of Directors authorized the issuance of 26,250 shares of the Company’s Series A preferred stock to Dr. Anil Diwan. The shares shall be vested in one-third increments on June 30, 2019, June 30, 2020 and June 30, 2021 and are subject to forfeiture. The Company recognized non-cash compensation expense related to the issuance of the Series A preferred stock of $47,260 and $94,520, respectively, for the three and six months ended December 31, 2019. The balance of $277,130 will be recognized as the shares vest and service is rendered. For the three and six months ended December 31, 2019, the Company’s Board of Directors authorized the issuance of 10,000 fully vested shares of its Series A preferred stock for a loan origination fee to a related party with fair value of $39,301. For the three and six months ended December 31, 2019, the Company's Board of Directors authorized the issuance of 100,000 fully vested shares of its Series A preferred stock with a fair value of $392,669 in exchange for $250,000 of previously deferred development fees to a related party and recognized a loss on the exchange of $142,669. For the three and six months ended December 31, 2019, the Company's Board of Directors authorized the issuance of 387 and 774, respectively, fully vested shares of its Series A preferred stock for employee compensation. The Company recorded expense of $2,134 and $6,272, respectively, for the three and six months ended December 31, 2019 related to these issuances. The fair value of the Series A Preferred stock was the following for the dates indicated: Date Shares Value 7/31/2019 129 1,472 8/31/2019 129 1,345 9/30/2019 129 1,321 10/31/2019 129 628 11/30/2019 129 677 12/16/2019 10,000 39,301 12/17/2019 100,000 392,669 12/31/2019 129 829 110,774 $ 438,242 There is currently no market for the shares of Series A Convertible Preferred Stock and they can only be converted into shares of Common Stock upon a Change of Control of the Company as more fully described in the Certificate of Designation. The Company, therefore, estimated the fair value of the Series A Convertible Preferred Stock granted to various employees and others on the date of grant. The Series A Convertible Preferred Stock fair value is based on the greater of i) the converted value to common at a ratio of 1:3.5; or ii) the value of the voting rights since the Holder would lose the voting rights upon conversion. The conversion of the shares is triggered by a Change of Control. The valuations of the Series A Convertible Preferred Stock at each issuance used the following inputs: a. The common stock price was in the range $2.03 to $2.60 b. The calculated weighted average number of shares of common stock in the period; c. A 26.63% premium over the common shares for the voting preferences; d. The calculated weighted average number of total voting shares and the monthly shares representing voting rights of 14.9% to 18.3% of the total; e. The conversion value is based on an assumption for calculation purposes only of a Change of Control in 4 years from October 31, 2016 and a remaining restricted term of 1.08 to .92 years; f. 29.30% to 46.06% restricted stock discount (based on a restricted stock analysis and call-put analysis curve: 80.41% to 81.54% volatility, 1.73% to 1.69% risk free rate) applied to the converted common shares. During the six months ended December 31, 2019, the SAB was granted in August 2019 fully vested warrants to purchase 572 shares of common stock with an exercise price of $5.88 per share expiring in August 2022 and in November 2019 572 fully vested warrants to purchase shares of common stock with an exercise price of $2.63 per share expiring in November 2023. The fair value of the warrants was $533 for the three months ended December 31, 2019 and $1,441 for the six months ended December 31, 2019 and was recorded as consulting expense. The Company estimated the fair value of the warrants granted to the Scientific Advisory Board on the date of grant using the Black-Scholes Option-Pricing Model with the following weighted-average assumptions: Expected life (year) Expected volatility 47.99-55.12 % Expected annual rate of quarterly dividends % Risk-free rate(s) 2.51-2.93 % For the three and six months ended December 31, 2019, the Company's Board of Directors authorized the issuance of 11,932 and 18,133, respectively fully vested shares of its common stock with a restrictive legend for consulting services. The Company recorded an expense of $27,000 and $54,000 for the three and six months ended December 31, 2019, respectively, which was the fair value on the dates of issuance. For the three and six months ended December 31, 2019, the Company’s Board of Directors authorized the issuance of 4,965 and 7,518, respectively, fully vested shares of its common stock with a restrictive legend for Director Services. The Company recorded an expense of $11,250 and $22,500 for the three and six months, respectively, which was the fair value on the dates of issuance.

Stock Warrants and Options

Stock Warrants and Options	6 Months Ended
	Dec. 31, 2019
Stock Warrants and Options
Stock Warrants and Options	Note 8 - Stock Warrants and Options Stock Warrants Weighted Average Weighted Exercise Average Price Remaining Aggregate Number of per share Contractual Term Intrinsic Value Stock Warrants Shares ($) (years) ($) Outstanding and exercisable at June 30, 2019 398,156 $ 18.20 4.69 $ — Granted 1,144 4.26 4.0 — Expired 29,288 77.61 — — Outstanding and exercisable at December 31, 2019 370,012 $ 13.45 4.53 $ — Of the above warrants 1,713 expire in fiscal year ending June 30, 2020, 2,858 expire in fiscal year ending June 30, 2021, 2,287 expire in the fiscal year ending June 30, 2022, 14,787 warrants expire in the fiscal year ending June 30, 2023, 1,142 warrants expire in the fiscal year ending June 30, 2024 and 347,225 expire in the fiscal year ending June 30, 2025. Stock Options Weighted Average Weighted Exercise Average Price Remaining Aggregate Number of per share Contractual Term Intrinsic Value Stock Options Shares ($) (years) ($) Outstanding at June 30, 2019 5,000 $ 10.00 2.17 $ — Granted — — — — Forfeited — — — — Outstanding at December 31, 2019 5,000 10.00 1.67 — The options expire on August 31, 2021

Fair Value Measurement

Fair Value Measurement	6 Months Ended
	Dec. 31, 2019
Fair Value Measurement
Fair Value Measurement	Note 9 - Fair Value Measurement Fair value measurements At December 31, 2019 and June 30, 2019 the estimated fair values of the liabilities measured on a recurring basis are as follows: Fair Value Measurements at December 31, 2019: (Level 1) (Level 2) (Level 3) Derivative liability - warrants $ — $ — $ 1,371,157 Fair Value Measurements at June 30, 2019: (Level 1) (Level 2) (Level 3) Derivative liability - warrants $ — $ — $ 1,645,606 In a concurrent private placement on February 27, 2019, the purchasers received warrants (the "Warrants") to purchase up to 347,223 shares of common stock. The Warrants have an exercise price of $12.20 per share, shall be exercisable on the six month anniversary of issuance and will expire five (5) years thereafter. The Warrants are exercisable for cash or, solely in the absence of an effective registration statement or prospectus, by cashless exercise. The Company accounts for stock purchase warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreements. Under applicable accounting guidance contained in ASU 2017-11, adopted by the Company on January 1, 2019, stock warrants are to be accounted for as equity if the warrants contain full-ratchet anti-dilution provisions. The warrants issued on February 27, 2019, contained a full-ratchet anti-dilution feature but also contained other adjustment features which required that the warrants be classified as a derivative liability. The Company used a lattice model to calculate the fair value of the derivative warrants based on a probability weighted discounted cash flow model. This model is based on future projections of the various potential outcomes. The features that were analyzed and incorporated into the model included the exercise and full reset provisions. The Warrants were valued as of December 31, 2019 and June 30, 2019 with the following assumptions: - The 5.5 year warrants issued on February 27, 2019 (expire February 27, 2024) included with an exercise price of $12.20 (subject to adjustments - full ratchet reset and fundamental transactions). - The stock price would fluctuate with the Company projected volatility. - The holder would exercise the warrant as they become exercisable (effective registration at issuance) at target prices of the higher of 2 times the projected reset exercise price or 2 times the stock price. - The holder would exercise the warrant at maturity if the stock price was above the project reset prices. - The next capital raise is projected to occur during 2020 (annually 12 months from issuance) at prices approximating 100% of market triggering a reset event and exercise price adjustment. - The fundamental transaction projected with 0% probability increasing 1% per quarter to maximum of 10% and settlement based on the Black Scholes value. - The stock price would fluctuate with an annual volatility. The projected volatility curve was based on historical volatilities of the Company for the valuation period. 1 Year 12/31/19 84.3 % 6/30/19 76.1 % The following tables present the activity for liabilities measured at estimated fair value using unobservable inputs for the six months ended December 31, 2019: Fair Value Measurement Fair Value Measurement Using Significant Unobservable Inputs Derivative Liability- Warrant Beginning balance at July 1, 2019 $ 1,645,606 Additions during the year — Change in fair value (274,449) Transfer in and out of Level 3 — Balance at December 31, 2019 $ 1,371,157

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Dec. 31, 2019
Commitments and Contingencies
Commitments and Contingencies	Note 10 - Commitments and Contingencies Legal Proceedings There are no pending legal proceedings against the Company to the best of the Company’s knowledge as of the date hereof and to the Company’s knowledge, no action, suit or proceeding has been threatened against the Company. See note 11 Subsequent Events. Employment Agreements The Company and Dr. Diwan, President and Chairman of the Board of Directors, entered into an extension of employment agreement effective July 1, 2018 for a term of three years. Dr. Diwan’s will be paid an annual base salary of $400,000. Additionally, Dr. Diwan was awarded a grant of 26,250 shares of the Company’s Series A preferred stock. 8,750 shares vest equally on June 30, 2019, 2020 and 2021. Any unvested shares are subject to forfeiture. The Company and Dr. Irach Taraporewala, the Company’s Chief Executive Officer, entered into an employment agreement effective September 1, 2018, for a term of three years. Dr. Taraporewala would be paid an annual base salary of $360,000. Additionally, Dr. Taraporewala was awarded a grant of 15,000 options to purchase shares of the Company’s common stock. 5,000 options vested on September 1, 2018 and the remainder of the options would vest over the two-year vesting period and are subject to forfeiture. On January 24, 2019, Dr. Taraporewala resigned as the Chief Executive Officer of the Company for personal reasons. Also on that date, the Company and Dr. Taraporewala agreed that Dr. Taraporewala would become a consultant for the Company for a period of two years. In connection with his resignation and new consulting services, the Company and Dr. Taraporewala entered into a Confidential Separation and Consulting Agreement and General Release (the "Agreement") pursuant to which the Company will pay Dr. Taraporewala monthly consulting payments of $3,000 from February 1, 2019, the effective date of the Agreement, through January 31, 2021. The Agreement includes a general release of claims against the Company, obligations of confidentiality, non-disclosure, non-disparagement and other customary provisions found in similar agreements. The remaining 10,000 options not vested upon resignation have been forfeited. On March 3, 2010, the Company entered into an employment agreement with Dr. Jayant Tatake to serve as Vice President of Research and Development. The employment agreement provides for a term of four years with a base salary of $150,000. In addition, the Company issued 1,340 shares of Series A preferred stock and 1,786 shares of common stock upon entering into the agreement, and issued an additional 1,340 shares of Series A Preferred stock and 1,786 shares of common stock on each anniversary date of the agreement. The shares of Series A Preferred Stock were issued in recognition of Dr. Tatake’s work towards the achievement of several patents by the Company. The Compensation Committee of the Board of Directors has extended the current provisions of the employment agreement pending its review of current industry compensation arrangements and employment agreements. On March 3, 2010, the Company entered into an employment agreement with Dr. Randall Barton to serve as Chief Scientific Officer. The employment agreement provided for a term of four years with a base salary of $150,000. In addition, the Company issued 1,786 shares of common stock upon entering into the agreement, and issued an additional 1,786 shares of common stock on each anniversary date of the agreement. The Compensation Committee of the Board of Directors has extended the current provisions of the employment agreement pending its review of current industry compensation arrangements and employment agreements. On May 30, 2013, the Company entered into an employment agreement with Meeta Vyas to serve as its Chief Financial Officer. The employment agreement provided for a term of three years with a base salary of $9,000 per month and 129 shares of Series A preferred stock, also on a monthly basis. On January 1, 2015, her cash compensation was increased to $10,800 per month. The agreement is renewable on an annual basis. The Compensation Committee of the Board of Directors has extended the current provisions of the employment agreement pending its review of current industry compensation arrangements and employment agreements. License Agreements The Company is dependent upon its license agreements with TheraCour (See Notes 1 and 4). If the Company lost the right to utilize any of the proprietary information that is the subject of the TheraCour license agreement on which it depends, the Company will incur substantial delays and costs in development of its drug candidates. On November 1, 2019, the Company entered into a Licensing Agreement (the "Agreement") with TheraCour for an exclusive license for the Company to use, promote, offer for sale, import, export, sell and distribute products for the treatment of VZV derived indications. Process development and related work will be performed by TheraCour under the same compensation terms as prior agreements between the parties, with no duplication of costs allowed. The Company was not required to make any upfront payments to TheraCour and agreed to the following milestone payments to TheraCour; the issuance of 75,000 shares of the Company's Series A preferred stock upon the grant of an IND Application; $1,500,000 in cash upon completion of Phase I Clinical Trials; $2,500,000 in cash upon completion of Phase II clinical trials; and $5,000,000 in cash upon completion of Phase III clinical trials.

Subsequent Events

Subsequent Events	6 Months Ended
	Dec. 31, 2019
Subsequent Events
Subsequent Events	Note 11 - Subsequent events On January 21, 2020, the Company entered into an Underwriting Agreement with Aegis Capital Corp. Pursuant to the terms and conditions of the Underwriting Agreement, we agreed to issue and sell 2,500,000 shares of our common stock, par value $0.001 per share, at a price to the public of $3.00 per share. Pursuant to the Underwriting Agreement, we also granted the underwriter an option to purchase up to an additional 375,000 shares of our common stock within 45 days after the date of the Underwriting Agreement to cover over-allotments, if any. The Final Prospectus for the offering was filed with the U.S. Securities and Exchange Commission pursuant to Rule 424(b)(1) of the Securities Act of 1933, as amended, on January 23, 2020. The offering was consummated on January 25, 2020. The Company sold the Underwritten Shares and the underwriter exercised its option to purchase an additional 375,000 shares of common stock at the public offering price of $3.00 per share. The net proceeds to the Company after underwriter's commission and agreed upon customary fees and expenses were approximately $7.78 million, before deducting the Company's legal and accounting expenses related to the Offering. On January 24, 2020, the Company entered into a Settlement Agreement and Mutual Release (the “Settlement Agreement”) with the investor parties (collectively, the “Investors”) to that certain Securities Purchase Agreement dated as of February 27, 2019 (the "Securities Purchase Agreement") to settle an action commenced by the Investors to, among other things, enjoin the Company’s previously disclosed underwritten public offering (the “Action”). The Company and each of the Investors agreed to enter into an Exchange Agreement with the Company to more fully implement the terms of a binding term sheet attached to the Settlement Agreement. As was previously disclosed, on February 27, 2019 we had entered into the Securities Purchase Agreement pursuant to which we issued the Investors an aggregate of 347,222 shares of our common stock, par value $0.001 per share (the “Common Stock”) and warrants (the “Old Warrants”) to purchase an additional 347,222 shares of Common Stock). On January 27, 2020, the Company entered into an Exchange Agreement with each of the Investors. Pursuant to the terms and conditions of the Exchange Agreement, the Investors agreed to terminate certain restrictive covenants in the Securities Purchase Agreement, including a bar on all offerings of securities below the exercise price of the Old Warrants, and the Company agreed to exchange all of the Investors’ Old Warrants for an aggregate of (i) 677,224 shares of Common Stock and (ii) warrants to purchase 347,222 shares of Common Stock at an exercise price of $3.00 per share (the “New Warrants”). The New Warrants are, subject to the availability of authorized shares of Common Stock of which there are none today, immediately exercisable and expire on August 27, 2024. The Exchange Agreement contains customary representations, warranties and covenants made by us. The Exchange Agreement closed on January 29, 2020. The exercise price of the New Warrants is subject to adjustment in the case of customary events such as stock dividends or other distributions on shares of common stock or any other equity or equity equivalent securities payable in shares of common stock, stock splits, stock combinations, reclassifications or similar events affecting our Common Stock, and also, subject to limitations, upon any distribution of assets, including cash, stock or other property to our stockholders and upon issuances of Common Stock below the exercise price of the New Warrants. The exercise of the New Warrants is subject to certain beneficial ownership and other limitations set forth in the New Warrants. On February 11, 2020, the Company and Dr. Diwan mutually agreed to extend the maturity date of the note at the Company’s option, to March 15, 2021, with the rest of the terms remaining the same.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Dec. 31, 2019
Summary of Significant Accounting Policies
Basis of Presentation	Basis of Presentation – Interim Financial Information The accompanying unaudited interim financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10‑Q and Article 10 of Regulation S-X of the Securities and Exchange Commission for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. The accompanying financial statements and the information included under the heading “Management’s Discussion and Analysis or Plan of Operation” should be read in conjunction with our Company’s audited financial statements and related notes included in our Company’s Form 10‑K for the fiscal year ended June 30, 2019 filed with the SEC on August 23, 2019. For a summary of significant accounting policies, see the Company’s Annual Report on Form 10‑K for the fiscal year ended June 30, 2019 filed on August 23, 2019.
Net Loss per Common Share	Net Loss per Common Share Basic net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants and convertible preferred stock. The following table shows the number of potentially outstanding dilutive common shares excluded from the diluted net loss per common share calculation, as they were anti-dilutive: Potentially Outstanding Dilutive Common Shares For the For the Six Months Six Months Ended Ended December 31, 2019 December 31, 2018 Options and Warrants 375,012 221,174 Total potentially outstanding dilutive common shares 375,012 221,174 The Company has also issued 366,488 shares of Series A preferred stock to investors and others as of December 31, 2019. Only in the event of a “change of control” of the Company, each Series A preferred share is convertible to 3.5 shares of its new common stock. A “Change of Control” is defined as an event in which the Company’s shareholders become 60% or less owners of a new entity as a result of a change of ownership, merger or acquisition of the Company or the Company’s intellectual property. In the absence of a Change of Control event, the Series A preferred stock is not convertible into common stock, and does not carry any dividend rights or any other financial effects. At December 31, 2019, the number of potentially dilutive shares of the Company’s common stock into which these Series A preferred shares can be converted into is 1,282,708 and is not included in diluted earnings per share since the shares are contingently convertible only upon a change of control.
Deferred Issuance Costs	Deferred Issuance Costs Deferred issuance costs consist of $383,175 of certain costs in connection with the Company’s S-1 registration and planned public offering. These costs together with any underwriter’s fees and discounts will be charged to additional paid-in capital upon closing of the public offering. note 11.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In July 2017, the FASB issued Accounting Standards Update (“ASU”) No. 2017‑11. “Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features, II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Non-controlling Interests with a Scope Exception (“ASU 2017-11”) ASU 2017‑11 revises the guidance for instruments with down round features in Subtopic 815‑40, Derivatives and Hedging – Contracts in Entity’s Own Equity, which is considered in determining whether an equity-linked financial instrument qualifies for a scope exception from derivative accounting. An entity still is required to determine whether instruments would be classified in equity under the guidance in Subtopic 815‑40 in determining whether they qualify for that scope exception. If they do qualify, freestanding instruments with down round features are no longer classified as liabilities. ASU 2017‑11 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018, and early adoption is permitted, including adoption in an interim period. ASU 2017‑11 provides that upon adoption, an entity may apply this standard retrospectively to outstanding financial instruments with a down round feature by means of a cumulative-effect adjustment to the opening balance of accumulated deficit in the fiscal year and interim period adoption. The Company has adopted ASU 2017-11 retrospectively as of January 1, 2019. The adoption of this ASU did not have any impact on its financial statements. In June 2018, the FASB issued ASU 2018-07, “Compensation – Stock Compensation (Topic 718) (“ASU 2018-07”): Improvements to Nonemployee Share Based Payment Accounting,” which simplifies the accounting for non-employee share-based payment transactions. The amendments specify that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. Upon transition, non-employee awards are required to be measured at fair value as of the adoption date. The Company had adopted ASU 2018-07 as of July 1, 2019. The adoption of this ASU did not have a significant impact on its financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Dec. 31, 2019
Summary of Significant Accounting Policies
Schedule of potentially outstanding dilutive common shares excluded from the diluted net loss per common share calculation	Potentially Outstanding Dilutive Common Shares For the For the Six Months Six Months Ended Ended December 31, 2019 December 31, 2018 Options and Warrants 375,012 221,174 Total potentially outstanding dilutive common shares 375,012 221,174

Related Party Transactions (Tab

Related Party Transactions (Tables)	6 Months Ended
	Dec. 31, 2019
Related Party Transactions
Summary of related parties	As of December 31, June 30, 2019 2019 Account Payable – Related Party Pursuant to an Exclusive License Agreement we entered into with TheraCour, the Company was granted exclusive licenses in perpetuity for technologies developed by TheraCour for the virus types: HIV, HCV, Herpes, Asian (bird) flu, Influenza and rabies. In consideration for obtaining this exclusive license, we agreed: (1) that TheraCour can charge its costs (direct and indirect) plus no more than 30% of direct costs as a development fee and such development fees shall be due and payable in periodic installments as billed, (2) we will pay $2,000 or actual costs each month, whichever is higher for other general and administrative expenses incurred by TheraCour on our behalf, (3) to make royalty payments of 15% (calculated as a percentage of net sales of the licensed drugs) to TheraCour; (4) to pay an advance payment equal to twice the amount of the previous month’s invoice to be applied as a prepayment towards expenses. On October 2, 2018, the Company entered into an agreement with TheraCour for a waiver of the two months worth of prepaid balance advance of anticipated invoicing until the filing of an IND and the application of the current advance as a credit against current open invoices. Additionally, TheraCour agreed to defer $25,000 per month of development fees, beginning with July 2018 through December 31, 2019. On December 17, 2019, the Company entered into a Deferred Expense Exchange Agreement with TheraCour, whereby the Company and TheraCour agreed to the exchange of 100,000 shares of Series A preferred stock with a fair value of $392,669 for $250,000 previously deferred development fees owed to TheraCour, and recognized a loss on the exchange of $142,669. Accounts payable due TheraCour on the reporting date was $ 737,370 $ 823,783 For the three months ended For the six months ended December December December December 31, 31, 31, 31, 2019 2018 2019 2018 Property and Equipment During the reporting period, TheraCour acquired property and equipment on behalf of the Company from third party vendors and sold such property and equipment, at cost, to the Company $ — $ 7,408 $ 4,139 $ 7,408 For the three months ended For the six months ended December December December December 31, 31, 31, 31, 2019 2018 2019 2018 Research and Development Costs Paid to Related Party Development fees and other costs charged by TheraCour pursuant to exclusive License Agreements between TheraCour and the Company for the development of the Company’s drug pipeline. No royalties are due TheraCour from the Company at December 31, 2019 and June 30, 2019 $ 543,108 $ 899,184 $ 1,119,315 $ 1,745,872
Schedule of mortgage note payable - related party	At December 31, 2019, mortgage note payable – related party consisted of: Mortgage note payable $ 1,100,000 Less: unamortized loan origination fee (37,663) $ 1,062,337

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Dec. 31, 2019
Property and Equipment
Schedule of property and equipment	December 31, June 30, 2019 2019 GMP Facility $ 8,020,471 $ 8,020,471 Land 260,000 260,000 Office Equipment 57,781 57,781 Furniture and Fixtures 5,607 5,607 Lab Equipment 5,752,457 5,748,318 Total Property and Equipment 14,096,316 14,092,177 Less Accumulated Depreciation (4,210,604) (3,864,930) Property and Equipment, Net $ 9,885,712 $ 10,227,247

Trademark and Patents (Tables)

Trademark and Patents (Tables)	6 Months Ended
	Dec. 31, 2019
Trademarks and Patents
Schedule of Trademark and patents, stated at cost, less accumulated amortization	December 31, June 30, 2019 2019 Trademarks and Patents $ 458,954 $ 458,954 Less Accumulated Amortization (96,431) (92,296) Trademarks and Patents, Net $ 362,523 $ 366,658

Equity Transactions (Tables)

Equity Transactions (Tables)	6 Months Ended
	Dec. 31, 2019
Schedule of estimation of estimated the fair value of the warrants granted	Expected life (year) Expected volatility 47.99-55.12 % Expected annual rate of quarterly dividends % Risk-free rate(s) 2.51-2.93 %
Series A Preferred stock
Schedule of fair value of Series A Preferred Stock	Date Shares Value 7/31/2019 129 1,472 8/31/2019 129 1,345 9/30/2019 129 1,321 10/31/2019 129 628 11/30/2019 129 677 12/16/2019 10,000 39,301 12/17/2019 100,000 392,669 12/31/2019 129 829 110,774 $ 438,242

Stock Warrants and Options (Tab

Stock Warrants and Options (Tables)	6 Months Ended
	Dec. 31, 2019
Stock Warrants and Options
Schedule of stock warrants activity	Weighted Average Weighted Exercise Average Price Remaining Aggregate Number of per share Contractual Term Intrinsic Value Stock Warrants Shares ($) (years) ($) Outstanding and exercisable at June 30, 2019 398,156 $ 18.20 4.69 $ — Granted 1,144 4.26 4.0 — Expired 29,288 77.61 — — Outstanding and exercisable at December 31, 2019 370,012 $ 13.45 4.53 $ —
Schedule of stock option activity	Weighted Average Weighted Exercise Average Price Remaining Aggregate Number of per share Contractual Term Intrinsic Value Stock Options Shares ($) (years) ($) Outstanding at June 30, 2019 5,000 $ 10.00 2.17 $ — Granted — — — — Forfeited — — — — Outstanding at December 31, 2019 5,000 10.00 1.67 —

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	6 Months Ended
	Dec. 31, 2019
Fair Value Measurement
Schedule of estimated fair values of the liabilities measured on a recurring basis	At December 31, 2019 and June 30, 2019 the estimated fair values of the liabilities measured on a recurring basis are as follows: Fair Value Measurements at December 31, 2019: (Level 1) (Level 2) (Level 3) Derivative liability - warrants $ — $ — $ 1,371,157 Fair Value Measurements at June 30, 2019: (Level 1) (Level 2) (Level 3) Derivative liability - warrants $ — $ — $ 1,645,606
Schedule of projected annual volatility	1 Year 12/31/19 84.3 % 6/30/19 76.1 %
Schedule of activity for liabilities measured at estimated fair value using unobservable inputs	The following tables present the activity for liabilities measured at estimated fair value using unobservable inputs for the six months ended December 31, 2019: Fair Value Measurement Fair Value Measurement Using Significant Unobservable Inputs Derivative Liability- Warrant Beginning balance at July 1, 2019 $ 1,645,606 Additions during the year — Change in fair value (274,449) Transfer in and out of Level 3 — Balance at December 31, 2019 $ 1,371,157

Organization ,Nature of Busin_2

Organization ,Nature of Business and Reverse Stock Split (Details)	Nov. 01, 2019USD ($)shares
Cash upon completion of Phase I Clinical Trials	$ 1,500,000
Cash upon completion of Phase II Clinical Trials	2,500,000
Cash upon completion of Phase III Clinical Trials	$ 5,000,000
Series A Convertible Preferred Stock [Member]
Issuance of shares | shares	75,000

Liquidity (Details)

Liquidity (Details) - USD ($)	Jan. 25, 2020	Jan. 21, 2020	Dec. 16, 2019	Dec. 07, 2019	Nov. 01, 2019	Dec. 31, 2019	Sep. 30, 2019	Dec. 31, 2018	Sep. 30, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 26, 2019	Jun. 30, 2019
Financial Condition [Line Items]
Retained Earnings (Accumulated Deficit)						$ (95,605,245)				$ (95,605,245)			$ (92,116,586)
Net loss						(1,927,526)	$ (1,561,133)	$ (2,230,992)	$ (1,841,463)	(3,488,659)	$ (4,072,455)
Net Cash Provided by (Used in) Operating Activities										(2,560,245)	(3,120,563)
Revenue										0	$ 0
Cash and cash equivalents						$ 707,648				$ 707,648			$ 2,555,207
Common Stock, Par or Stated Value Per Share						$ 0.001				$ 0.001			$ 0.001
Common stock, par value (in dollars per share)						0.001				0.001			$ 0.001
Underwriters option to purchase additional shares (in shares)		375,000
Over Allotment Option | Subsequent event
Financial Condition [Line Items]
Common Stock, Par or Stated Value Per Share		$ 0.001
Common stock, shares issued and sold (in shares)		2,500,000
Common stock, par value (in dollars per share)		$ 0.001
Public offering price (in dollars per share)	$ 3	$ 3
Underwriters option to purchase additional shares (in shares)	375,000	375,000
Period to avail over-allotment option		45 days
Underwriter's commission and agreed upon customary fees and expenses	$ 7,780,000	$ 7,800,000
Maximum [Member] | Series A Preferred stock
Financial Condition [Line Items]
Public offering price (in dollars per share)						$ 2.60				$ 2.60
TheraCour
Financial Condition [Line Items]
Common stock, shares issued and sold (in shares)					75,000
TheraCour | Series A Preferred stock
Financial Condition [Line Items]
Deferred development fees exchanged for shares				$ 250,000
Series A shares issued in exchange of deferred development fees owed (in shares)			10,000	100,000
Open End Mortgage Note | Anil Diwan
Financial Condition [Line Items]
Drew down amount						$ 1,100,000				$ 1,100,000
Open End Mortgage Note | Anil Diwan | Maximum [Member]
Financial Condition [Line Items]
Amount of loan			$ 2,000,000									$ 2,000,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Warrants and Options (Details) - shares	6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Accounting Policies [Line Items]
Total potentially outstanding dilutive common shares	375,012	221,174
Options and Warrants [Member]
Accounting Policies [Line Items]
Total potentially outstanding dilutive common shares	375,012	221,174

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Net Loss per Common Share - Preferred Stock (Details)	Dec. 31, 2019shares
Summary of Significant Accounting Policies
Convertible Preferred Stock, Shares Issued upon Conversion	3.5
Convertible Preferred Stock, Change in Control, Ownership Percentage in New Entity, Maximum	60.00%

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)	6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Jun. 30, 2019
Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	375,012	221,174
Deferred issuance costs	$ 383,175
Series A Convertible Preferred Stock [Member]
Accounting Policies [Line Items]
Preferred Stock, Shares Issued	366,488		255,714
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,282,708

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	Oct. 02, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Jun. 30, 2019
Research and development		$ 1,012,085	$ 1,657,838	$ 2,494,490	$ 3,024,779
TheraCour
Account Payable - Related Party		737,370		737,370		$ 823,783
Property and Equipment			7,408	4,139	7,408
Research and development	$ 25,000	$ 543,108	$ 899,184	$ 1,119,315	$ 1,745,872

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Details)	Dec. 17, 2019USD ($)shares	Dec. 16, 2019USD ($)shares	Dec. 07, 2019USD ($)shares	Oct. 02, 2018USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2019USD ($)shares	Dec. 31, 2018USD ($)	Sep. 30, 2019USD ($)	Jun. 30, 2019USD ($)
Related Party Transaction [Line Items]
Other General and Administrative Expense					$ 2,000
Percentage of Direct Costs					30.00%
Percentage Of Net Sales Allocated For Royalty Payments					15.00%
Research and Development Expense					$ 1,012,085	$ 1,657,838	$ 2,494,490	$ 3,024,779
Accrued Royalties									$ 0	$ 0
Amortization expense on loan origination fee							(1,638)	0
Loss on exchange of shares					142,669		142,669
TheraCour
Related Party Transaction [Line Items]
Research and Development Expense				$ 25,000	543,108	$ 899,184	$ 1,119,315	$ 1,745,872
Series A Preferred stock
Related Party Transaction [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross | shares		10,000					110,774
Stock Issued During Period, Value, Share-based Compensation, Gross		$ 39,301					$ 438,242
Converted value to common shares		0.285
Amortization expense on loan origination fee					$ 1,638		$ 1,638
Series A Preferred stock | TheraCour
Related Party Transaction [Line Items]
Series A shares issued in exchange of deferred development fees owed (in shares) | shares		10,000	100,000
Deferred development fees exchanged for shares			$ 250,000
Series A Preferred stock | TheraCour
Related Party Transaction [Line Items]
Series A shares issued in exchange of deferred development fees owed (in shares) | shares	100,000
Stock Issued During Period, Value, Share-based Compensation, Gross	$ 392,669
Deferred development fees exchanged for shares	250,000
Loss on exchange of shares	$ 142,669

Related Party Transactions - Mo

Related Party Transactions - Mortgage Note Payable - Related Party (Details)	Dec. 16, 2019USD ($)itemshares	Dec. 07, 2019shares	Dec. 31, 2019USD ($)	Dec. 31, 2019USD ($)	Dec. 26, 2019USD ($)
Related Party Transaction [Line Items]
Amount of interest payable escrowed			$ 132,000	$ 132,000
Amount of interest expense which reduced the interest escrow retained by the lender			2,493	2,493
TheraCour | Series A Preferred stock
Related Party Transaction [Line Items]
Series A shares issued in exchange of deferred development fees owed (in shares) | shares	10,000	100,000
Open End Mortgage Note | Anil Diwan
Related Party Transaction [Line Items]
Number of tranches | item	2
Amount of loan per tranche	$ 1,000,000
Interest rate per annum (as a percent)	12.00%
Drew down amount			$ 1,100,000	$ 1,100,000
Open End Mortgage Note | Anil Diwan | Maximum [Member]
Related Party Transaction [Line Items]
Amount of loan	$ 2,000,000				$ 2,000,000

Related Party Transactions - _2

Related Party Transactions - Mortgage Note Payable - Related Party Tabular Information (Details)	Dec. 31, 2019USD ($)
Related Party Transactions
Mortgage note payable	$ 1,100,000
Less: unamortized loan origination fee	(37,663)
Total	$ 1,062,337

Property and Equipment - Proper

Property and Equipment - Property and Equipment (Details) - USD ($)	Dec. 31, 2019	Jun. 30, 2019
Property and Equipment
GMP Facility	$ 8,020,471	$ 8,020,471
Land	260,000	260,000
Office Equipment	57,781	57,781
Furniture and Fixtures	5,607	5,607
Lab Equipment	5,752,457	5,748,318
Total Property and Equipment	14,096,316	14,092,177
Less Accumulated Depreciation	(4,210,604)	(3,864,930)
Property and Equipment, Net	$ 9,885,712	$ 10,227,247

Property and Equipment - Additi

Property and Equipment - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Property and Equipment
Depreciation	$ 172,863	$ 171,815	$ 345,674	$ 343,135

Trademark and Patents - Tradema

Trademark and Patents - Trademarks and Patents (Details) - USD ($)	Dec. 31, 2019	Jun. 30, 2019
Trademarks and Patents
Trademarks and Patents	$ 458,954	$ 458,954
Less Accumulated Amortization	(96,431)	(92,296)
Trademarks and Patents, Net	$ 362,523	$ 366,658

Trademark and Patents - Additio

Trademark and Patents - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Trademarks and Patents
Amortization	$ 2,067	$ 2,067	$ 4,135	$ 4,136

Equity Transactions - Fair Valu

Equity Transactions - Fair Value of Series A Preferred stock (Details) - Series A Preferred stock - USD ($)	Dec. 16, 2019	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross	10,000	110,774
Stock Issued During Period, Value, Share-based Compensation, Gross	$ 39,301	$ 438,242
Issuance Date One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross		129
Stock Issued During Period, Value, Share-based Compensation, Gross		$ 1,472
Issuance Date Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross		129
Stock Issued During Period, Value, Share-based Compensation, Gross		$ 1,345
Issuance Date Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross		129
Stock Issued During Period, Value, Share-based Compensation, Gross		$ 1,321
Issuance Date Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross		129
Stock Issued During Period, Value, Share-based Compensation, Gross		$ 628
Issuance Date Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross		129
Stock Issued During Period, Value, Share-based Compensation, Gross		$ 677
Issuance Date Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross		10,000
Stock Issued During Period, Value, Share-based Compensation, Gross		$ 39,301
Issuance Date Seven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross		100,000
Stock Issued During Period, Value, Share-based Compensation, Gross		$ 392,669
Issuance Date Eight [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross		129
Stock Issued During Period, Value, Share-based Compensation, Gross		$ 829

Equity Transactions - CEO (Deta

Equity Transactions - CEO (Details) - Chief Executive Officer [Member]	6 Months Ended
	Dec. 31, 2019
Expected life (year)	4 years
Expected annual rate of quarterly dividends	0.00%
Maximum [Member]
Expected volatility	55.12%
Risk-free rate(s)	2.93%
Minimum [Member]
Expected volatility	47.99%
Risk-free rate(s)	2.51%

Equity Transactions - Warrants

Equity Transactions - Warrants - Fair Value Assumptions (Details)	Dec. 31, 2019
Scientific Advisory Board Common Stock Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Valuation Technique	us-gaap:ValuationTechniqueOptionPricingModelMember

Equity Transactions - Additiona

Equity Transactions - Additional Information (Details) - USD ($)	Dec. 16, 2019	Nov. 01, 2019	Feb. 27, 2019	Jul. 11, 2018	Oct. 31, 2016	Dec. 31, 2019	Dec. 31, 2019	Jun. 30, 2019	Jun. 11, 2018
Class of Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 12.20
Convertible Preferred Stock, Shares Issued upon Conversion						3.5	3.5
Loss on exchange of shares						$ 142,669	$ 142,669
Fair Value Adjustment of Warrants						$ 533	$ 1,441
Warrant Expiration Term			5 years 6 months
Percentage of Market Triggering Event			100.00%
Common Stock, Par or Stated Value Per Share						$ 0.001	$ 0.001	$ 0.001
Share-based Compensation Award, Tranche One [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares							8,750
Derivative liability - Warrants
Class of Stock [Line Items]
Number Of Common Stock To Be Issued Upon Conversion Of Warrants							572
Derivative liability - Warrants | August 2022
Class of Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights						5.88	$ 5.88
Derivative liability - Warrants | November 2023
Class of Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 2.63	$ 2.63
Director [Member]
Class of Stock [Line Items]
Share-based Compensation						$ 11,250	$ 22,500
Stock Issued During Period, Shares, Share-based Compensation, Gross						4,965	7,518
Chief Executive Officer [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period							2 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term							4 years
Chief Executive Officer [Member] | Minimum [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate							47.99%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate							2.51%
Chief Executive Officer [Member] | Maximum [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate							55.12%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate							2.93%
Consulting Services [Member]
Class of Stock [Line Items]
Share-based Compensation						$ 27,000	$ 54,000
Stock Issued During Period, Shares, Share-based Compensation, Gross						11,932	18,133
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage				33.33%
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options									$ 277,130
Preferred Stock, Shares Authorized						425,000	425,000	425,000
Stock Issued During Period, Shares, New Issues		75,000
Series A Convertible Preferred Stock [Member] | Director [Member]
Class of Stock [Line Items]
Loan origination fees							$ 39,301
Stock Issued During Period, Value, Share-based Compensation, Gross						$ 392,669	$ 392,669
Series A Preferred stock
Class of Stock [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award, Voting Rights, Percentage							26.63%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term					4 years
Stock Issued During Period, Value, Share-based Compensation, Gross	$ 39,301						$ 438,242
Stock Issued During Period, Shares, Share-based Compensation, Gross	10,000						110,774
Series A Preferred stock | Minimum [Member]
Class of Stock [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award, Voting Rights, Percentage							14.90%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term							11 months 1 day
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions							29.30%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate							80.41%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate							1.73%
Share Price						$ 2.03	$ 2.03
Series A Preferred stock | Maximum [Member]
Class of Stock [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award, Voting Rights, Percentage							18.30%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term							1 year 29 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions							46.06%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate							81.54%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate							1.69%
Share Price						$ 2.60	$ 2.60
Series A Preferred stock | Director [Member]
Class of Stock [Line Items]
Stock issued for debt (in shares)						10,000	10,000
Stock Issued During Period, Shares, In Exchange For Deferred Development Fees						100,000	100,000
Deferred development fees exchanged for shares						$ 250,000	$ 250,000
Series A Preferred stock | President [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period				26,250
Share-based Compensation						$ 47,260	$ 94,520
Series A Preferred stock | Employee Compensations [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period						387	774
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares						2,134	6,272

Stock Warrants and Options - (D

Stock Warrants and Options - (Details) - Stock Warrants - USD ($)	6 Months Ended	12 Months Ended
	Dec. 31, 2019	Jun. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding and exercisable	398,156
Number of Shares, Granted	1,144
Number of Shares, Expired	29,288
Number of Shares, Outstanding and exercisable	370,012	398,156
Weighted Average Exercise Price per share, Outstanding and exercisable (dollars per share)	$ 18.20
Weighted Average Exercise Price per share, Granted (dollars per share)	4.26
Weighted Average Exercise Price per share, Expired (dollars per share)	77.61
Weighted Average Exercise Price per share, Outstanding and exercisable (dollars per share)	$ 13.45	$ 18.20
Weighted Average Remaining Contractual Term (years), Granted	4 years
Weighted Average Remaining Contractual Term (years), Expired	0 years
Weighted Average Remaining Contractual Term (years), Outstanding and exercisable	4 years 6 months 11 days	4 years 8 months 9 days
Aggregate Intrinsic Value, Outstanding and exercisable (in dollars)	$ 0	$ 0
Aggregate Intrinsic Value, Granted (in dollars)	0
Aggregate Intrinsic Value, Expired (in dollars)	$ 0

Stock Warrants and Options - St

Stock Warrants and Options - Stock options - (Details) - Equity Option - USD ($)	6 Months Ended	12 Months Ended
	Dec. 31, 2019	Jun. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding and exercisable	5,000
Number of Shares, Granted	0
Number of Shares, Forfeited	0
Number of Shares, Outstanding and exercisable	5,000	5,000
Weighted Average Exercise Price per share, Outstanding and exercisable (dollars per share)	$ 10
Weighted Average Exercise Price per share, Granted (dollars per share)	0
Weighted Average Exercise Price per share, Forfeited (dollars per share)	0
Weighted Average Exercise Price per share, Outstanding and exercisable (dollars per share)	$ 10	$ 10
Weighted Average Remaining Contractual Term (years), Granted	0 years
Weighted Average Remaining Contractual Term (years), Forfeited	0 years
Weighted Average Remaining Contractual Term (years), Outstanding and exercisable	1 year 8 months 1 day	2 years 2 months 1 day
Aggregate Intrinsic Value, Outstanding and exercisable (in dollars)	$ 0	$ 0
Aggregate Intrinsic Value, Granted (in dollars)	0
Aggregate Intrinsic Value, Forfeited (in dollars)	$ 0

Stock Warrants and Options - Ad

Stock Warrants and Options - Additional Information (Details)	6 Months Ended
	Dec. 31, 2019shares
June 30, 2020 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercisable	1,713
June 30, 2021 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercisable	2,858
June 30 2022 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercisable	2,287
June 30, 2023 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercisable	14,787
June 30 2024 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercisable	1,142
June 30, 2025 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercisable	347,225

Fair Value Measurement - Estima

Fair Value Measurement - Estimated Fair Values of Liabilities Measured on Recurring Basis (Details) - Derivative liability - Warrants - USD ($)	Dec. 31, 2019	Jun. 30, 2019
Fair Value, Inputs, Level 1 [Member]
Derivative Liability, Noncurrent	$ 0	$ 0
Fair Value, Inputs, Level 2 [Member]
Derivative Liability, Noncurrent	0	0
Fair Value, Inputs, Level 3 [Member]
Derivative Liability, Noncurrent	$ 1,371,157	$ 1,645,606

Fair Value Measurement - Projec

Fair Value Measurement - Projected Annual Volatility (Details)	Sep. 30, 2018	Dec. 31, 2019
One Year Ended 12/31/19
Fair Value Assumption Expected Volatility Rate	84.30%
One Year Ended 6/30/19
Fair Value Assumption Expected Volatility Rate		76.10%

Fair Value Measurement - Esti_2

Fair Value Measurement - Estimated Fair Value Using Unobservable Inputs (Details)	6 Months Ended
	Dec. 31, 2019USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 1,645,606
Additions during the year	0
Change in fair value - transfer in and out of Level	(274,449)
Ending Balance	$ 1,371,157

Fair Value Measurement - Additi

Fair Value Measurement - Additional Information (Details) - $ / shares	Feb. 27, 2019	Dec. 31, 2019
Warrant Expiration Term	5 years 6 months
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 12.20
Percentage of Market Triggering Event	100.00%
Derivative liability - Warrants
Class of Warrant or Right, Outstanding	347,223
Warrant Expiration Term	5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 12.20
Percentage of Probability		0.00%
Derivative liability - Warrants | Maximum [Member]
Percentage of Probability		10.00%
Derivative liability - Warrants | Minimum [Member]
Percentage of Probability		1.00%

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($)	Nov. 01, 2019	Jul. 11, 2018	Jan. 01, 2015	May 30, 2013	Mar. 03, 2010	Dec. 31, 2019	Sep. 30, 2018	Dec. 31, 2019	Jun. 30, 2019
Commitments and Contingencies [Line Items]
Common stock, shares issued						3,870,572		3,870,572	3,844,921
Deferred Compensation Arrangement with Individual, Compensation Expense								$ 400,000
Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance						26,250		26,250
Employment Agreement Term								3 years
Cash upon completion of Phase I Clinical Trials	$ 1,500,000
Cash upon completion of Phase II Clinical Trials	2,500,000
Cash upon completion of Phase III Clinical Trials	$ 5,000,000
Share-based Compensation Award, Tranche One [Member]
Commitments and Contingencies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares								8,750
TheraCour
Commitments and Contingencies [Line Items]
Stock Issued During Period, Shares, New Issues	75,000
Cash upon completion of Phase I Clinical Trials	$ 1,500,000
Cash upon completion of Phase II Clinical Trials	2,500,000
Cash upon completion of Phase III Clinical Trials	$ 5,000,000
Series A Convertible Preferred Stock [Member]
Commitments and Contingencies [Line Items]
Preferred stock, shares issued						366,488		366,488	255,714
Stock Issued During Period, Shares, New Issues	75,000
Chief Executive Officer [Member]
Commitments and Contingencies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period								2 years
Employment Agreement Term							3 years
Chief Executive Officer [Member] | Year One [Member]
Commitments and Contingencies [Line Items]
Deferred Compensation Arrangement with Individual, Compensation Expense								$ 360,000
Chief Executive Officer [Member] | Year Two [Member]
Commitments and Contingencies [Line Items]
Deferred Compensation Arrangement with Individual, Compensation Expense								15,000
Chief Executive Officer [Member] | Year Three [Member]
Commitments and Contingencies [Line Items]
Deferred Compensation Arrangement with Individual, Compensation Expense								5,000
Chief Scientific Officer [Member]
Commitments and Contingencies [Line Items]
Common stock, shares issued					1,786
Additional Common Stock Shares Issued					1,786
Increase In Base Salary					$ 150,000
Employment Agreement Term					4 years
President [Member] | Series A Preferred stock
Commitments and Contingencies [Line Items]
Share-based Compensation						$ 47,260		$ 94,520
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period		26,250
Vice President [Member]
Commitments and Contingencies [Line Items]
Common stock, shares issued					1,786
Additional Common Stock Shares Issued					1,786
Preferred stock, shares issued					1,340
Additional Preferred Stock Shares Issued					1,340
Increase In Base Salary					$ 150,000
Employment Agreement Term					4 years
Chief Financial Officer [Member]
Commitments and Contingencies [Line Items]
Increase In Base Salary			$ 10,800	$ 9,000
Employment Agreement Term				3 years
Chief Financial Officer [Member] | Series A Convertible Preferred Stock [Member]
Commitments and Contingencies [Line Items]
Preferred stock, shares issued				129
Mr Taraporewala [Member]
Commitments and Contingencies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period								2 years
Consulting Services Payments						$ 3,000		$ 3,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares								10,000

Subsequent Events (Details)

Subsequent Events (Details) - USD ($) $ / shares in Units, $ in Thousands	Jan. 27, 2020	Jan. 25, 2020	Jan. 21, 2020	Nov. 01, 2019	Feb. 27, 2019	Dec. 31, 2019	Jun. 30, 2019
Subsequent Event [Line Items]
Common Stock, Par or Stated Value Per Share						$ 0.001	$ 0.001
Underwriters option to purchase additional shares (in shares)			375,000
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 12.20
Exchange Agreement | Subsequent event
Subsequent Event [Line Items]
Common stock, shares issued and sold (in shares)	677,224
Warrants to purchase additional shares (in shares)	347,222
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 3
Over Allotment Option | Subsequent event
Subsequent Event [Line Items]
Common stock, shares issued and sold (in shares)			2,500,000
Common Stock, Par or Stated Value Per Share			$ 0.001
Share Price		$ 3	$ 3
Underwriters option to purchase additional shares (in shares)		375,000	375,000
Period to avail over-allotment option			45 days
Underwriter's commission and agreed upon customary fees and expenses		$ 7,780	$ 7,800
Securities Purchase Agreement
Subsequent Event [Line Items]
Common stock, shares issued and sold (in shares)					347,222
Common Stock, Par or Stated Value Per Share					$ 0.001
Warrants to purchase additional shares (in shares)					347,222
Series A Convertible Preferred Stock [Member]
Subsequent Event [Line Items]
Common stock, shares issued and sold (in shares)				75,000